Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)